Molecular Templates to Present Clinical Data at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018

World News: . []

ASCO Posters to Feature Data on MT-3724 and Evofosfamide

AUSTIN, Texas, May 16, 2018 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies, a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that data on two of its pipeline programs will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, to be held June 1-5 in Chicago, Illinois.

The poster summarizes interim results from a Phase I study of B-cell non-Hodgkin’s lymphoma (NHL) patients treated with MT-3724 who had previously relapsed after prior response to anti-CD20 Mab and chemotherapy. The results showed that MT-3724 has clinical anti-tumor activity in heavily pre-treated patients with relapsed or refractory B-cell NHL.  Consistent with the mechanism of action, the best activity is observed in patients with rapidly growing diffuse large B-cell lymphoma (DLBCL).  

This study compares the pharmacokinetic (PK) profile of Evofosfamide from the Phase II and Phase III trials completed in patients with pancreatic ductal adenocarcinoma (PDAC).  A new ethanol-based formulation of Evofosfamide was introduced following Phase 2, with the goal of improving drug product solubility. The resultant decrease in drug exposure may explain why the efficacy seen in the Phase 2 study was not replicated in Phase 3. 

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual events or results may differ materially from those discussed in the forward-looking statements as a result of various factors including, but not limited to, the uncertainties inherent in the preclinical and clinical development process;  whether the Company’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; the ability of the Company to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as those risks identified under the heading “Risk Factors” in the Company’s filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether because of new information, future events or otherwise.

Adam CutlerChief Financial Officer 862-204-4006

Source: Molecular Templates, Inc.

More news and information about Molecular Templates, Inc.

Published By:

Globe Newswire: 22:00 GMT Wednesday 16th May 2018

Published: .

Search for other references to "molecular" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers